Jasper Therapeutics (NASDAQ:JSPR) Earns Outperform Rating from Analysts at BMO Capital Markets

BMO Capital Markets started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note issued to investors on Friday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $63.00 price target on the stock. BMO Capital Markets’ target price would indicate a potential upside of 192.61% from the company’s previous close.

A number of other equities analysts also recently issued reports on JSPR. Royal Bank of Canada cut their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research note on Wednesday, August 14th. Evercore ISI reiterated an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research report on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $73.38.

Jasper Therapeutics Stock Down 6.8 %

Shares of Jasper Therapeutics stock opened at $21.53 on Friday. The firm has a market cap of $322.95 million, a price-to-earnings ratio of -4.54 and a beta of 2.18. Jasper Therapeutics has a 52-week low of $4.00 and a 52-week high of $31.01. The company’s 50-day simple moving average is $20.47 and its 200-day simple moving average is $20.94.

Institutional Trading of Jasper Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Samsara BioCapital LLC raised its position in shares of Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after purchasing an additional 59,642 shares during the last quarter. Ally Bridge Group NY LLC increased its position in Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after buying an additional 180,852 shares in the last quarter. Braidwell LP acquired a new position in shares of Jasper Therapeutics in the third quarter worth $9,091,000. Bank of New York Mellon Corp purchased a new stake in shares of Jasper Therapeutics in the second quarter valued at $740,000. Finally, American Century Companies Inc. boosted its stake in shares of Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after acquiring an additional 3,032 shares during the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.